Csm Advisors, LLC Gilead Sciences, Inc. Transaction History

Csm Advisors, LLC

$1.52 Billion
Q1 2024

A detailed history of Csm Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Csm Advisors, LLC holds 68,275 shares of GILD stock, worth $4.55 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

68,275

Previous 69,625 1.94%

Holding current value

$4.55 Million

Previous $5.64 Million 11.31%

% of portfolio

0.33%

Previous 0.41%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $96,633 - $117,841	-1,350 Reduced 1.94%	68,275 $5 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $72,903 - $82,674	-995 Reduced 1.41%	69,625 $5.64 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $221,450 - $241,606	-2,995 Reduced 4.07%	70,620 $5.29 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $87,411 - $99,705	-1,150 Reduced 1.54%	73,615 $5.67 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $122,147 - $175,361	-1,960 Reduced 2.55%	74,765 $6.42 Million

Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1.21 Million - $1.38 Million	-20,255 Reduced 20.89%	76,725 $4.73 Million
Q2 2022 Aug 11, 2022	SELL	$57.72 - $65.01 $577 - $650	-10 Reduced 0.01%	96,980 $6 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $544,448 - $682,252	-9,400 Reduced 8.84%	96,990 $5.77 Million
Q4 2021 Feb 09, 2022	SELL	$64.88 - $73.64 $228,377 - $259,212	-3,520 Reduced 3.2%	106,390 $7.73 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $335,121 - $366,167	-5,280 Reduced 4.58%	109,910 $7.57 Million
Q1 2021 May 21, 2021	BUY	$60.0 - $68.46 $6.91 Million - $7.89 Million	115,190 New	115,190 $7.45 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Csm Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Csm Advisors, LLC with notifications on news.

Account